The mammalian tachykinin ligand-receptor system: An emerging target for central neurological disorders

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 5, 2010, Pages 627-635

  Pantaleo, Nick ^a   Chadwick, Wayne ^a   Park, Sung Soo ^a   Wang, Liyun ^a   Zhou, Yu ^a   Martin, Bronwen ^a   Maudsley, Stuart ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Central neurological disorders; Neurokinin A; Neurokinin B; Neurotherapeutics; Receptor ligand systems; Substance P; Tachykinin

Indexed keywords

APREPITANT; AZD 2624; DEXAMETHASONE; FOSAPREPIPANT; G PROTEIN COUPLED RECEPTOR; LY 686017; NEUROKININ A; NEUROKININ B; ORVEPITANT; SEROTONIN 3 ANTAGONIST; SSR 241586; SUBSTANCE P; TACHYKININ RECEPTOR; TACHYKININ RECEPTOR AGONIST; TACHYKININ RECEPTOR ANTAGONIST; TALNETANT; UNCLASSIFIED DRUG; VESTIPITANT; VOFOPITANT;

ADDICTION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CENTRAL NERVOUS SYSTEM; CHEMOTHERAPY INDUCED EMESIS; EPILEPSY; FIBROMYALGIA; HUMAN; HUNTINGTON CHOREA; MACHADO JOSEPH DISEASE; MOOD DISORDER; MOTOR DYSFUNCTION; MOTOR NEURON DISEASE; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROPHYSIOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; POSTTRAUMATIC STRESS DISORDER; SIGNAL TRANSDUCTION; SLEEP DISORDER; TRAUMATIC BRAIN INJURY;

EID: 78649240500     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710793361504     Document Type: Article

References (135)

1. Tatemoto, K.; Lundberg, J.M.; Jörnvall, H.; Mutt, V. Neuropeptide K: isolation, structure and biological activities of a novel brain tachykinin. Biochem. Biophys. Res. Commun., 1985, 128(2), 947-953.
2. Kage, R.; McGregor, G.P.; Thim, L.; Conlon, J.M. Neuropeptide-gamma: a peptide isolated from rabbit intestine that is derived from gamma-preprotachykinin. J. Neurochem., 1988, 50(5), 1412-1417.
3. Kurtz, M.M.; Wang, R.; Clements, M.K.; Cascieri, M.A.; Austin, C.P.; Cunningham, B.R.; Chicchi, G.G.; Liu, Q. Identification, localization and receptor characterization of novel mammalian substance P-like peptides. Gene, 2002, 296(1-2), 205-212.
4. Von Euler, U.S.; Gaddum, J.H. An unidentified depressor substance in certain tissue extracts. J. Physiol., 1931, 72(1), 74-87.
5. Erspamer, V.; Espamer, G.F. Pharmacological actions of eledoisin on extravascular smooth muscle. Br. J. Pharmacol., 1962, 19(2), 337-354.
6. Chang, M.M.; Leeman, S.E.; Niall, H.D. Amino-acid sequence of substance P. Nat. New. Biol., 1971, 232(29), 86-87.
7. Kangawa, K.; Minamino, N.; Fukuda, A.; Matsuo, H. Neuromedin K: a novel mammalian tachykinin identified in porcine spinal cord. Biochem. Biophys. Res. Commun., 1983, 114(2), 533-540.
8. Kimura, S.; Okada, M.; Sugita, Y.; Kanazawa, I.; Munekate, E. Novel neuropeptides, neurokinin and, isolated from porcine spinal cord. Proc. Jpn. Acad. B, 1983, 59(1), 101-104.
9. Regoli, S.; Boudon, A.; Fauchére, J.L. Receptors and antagonists for substance P and related peptides. Pharmacol. Rev., 1994, 46(4), 551-599.
10. Zhang, Y.; Lu, L.; Furlonger, C.; Wu, G.E.; Paige, C.J. Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis. Nat. Immunol., 2000, 1(5), 392-397.
11. Almeida, T.A.; Rojo, J.; Nieto, P.M.; Pinto, F.M.; Hernandez, M.; Martín, J.D.; Candenas, M.L. Tachykinins and tachykinin receptors: structure and activity relationships. Curr. Med. Chem., 2004, 11(15), 2045-2081.
12. Ohkubo, H.; Nakanishi, S. Molecular characterization of the three tachykinin receptors. Ann. N. Y. Acad. Sci., 1991, 632, 53-62.
13. Maggi, C.A. The mammalian tachykinin receptors. Gen. Pharmacol., 1995, 26(5), 911-944.
14. Maudsley, S.; Carpenter, E.; Gent, J.P. Receptor characterization of the NK1 receptor on NG108-15 cells. Br. J. Pharmacol., 1993, 110, 175.
15. Gerard, N.P.; Bao, L.; Xiao-Ping, H.; Gerard, C. Molecular aspects of the tachykinin receptors. Regul. Pept., 1993, 43(1-2), 21-35.
16. Maudsley, S.; Gent, J. P. Tachykinin-induced activation of a non-selective cation conductance in ND7/23 cells. Br. J. Pharmacol., 1995, 116, 444.
17. Phenna, S.; Carpenter, E.; Peers, C.; Maudsley, S.; Gent, J. P. Inhibition of Ca2+-sensitive K+ currents in NG108-15 cells by substance P and related tachykinins. Br. J. Pharmacol., 1996, 119, 315-320.
18. Maudsley, S.; Gent, J.P.; Findlay, J.B.; Donnelly, D. The relationship between the agonist-induced activation and desensitization of the human tachykinin NK2 receptor expressed in Xenopus oocytes. Br. J. Pharmacol., 1998, 124(4), 675-684.
19. Mantyh, P.W. Neurobiology of substance P and the NK1 receptor. J. Clin. Psychiatry, 2002, 63(11), 6-10.
20. Herpfer, I.; Lieb, K. Substance P and Substance P receptor antagonists in the pathogenesis and treatment of affective disorders. World J. Biol. Psychiatry, 2003, 4(2), 56-63.
21. Schedlowski, M.; Fluge, T.; Richter, S.; Tewes, U.; Schmidt, R.E.; Wagner, T.O. Beta-endorphin, but not substance-P, is increased by acute stress in humans. Psychoneuroendocrinology, 1995, 20(1), 103-110.
22. Weiss, D.W.; Hirt.R.; Tarcic, N.; Berzon, Y.; Ben-Zur, H.; Breznitz, S.; Glaser, B.; Grover, N.B.; Baras, M.; O'Dorisio, T.M. Studies in psychoneuroimmunology: psychological, immunological, and neuroendocrinological parameters in Israeli civilians during and after a period of Scud missile attacks. Behav. Med., 1996, 22(1), 5-14.
23. Bondy, B.; Baghai, T.C.; Minov, C.; Schüle, C.; Schwarz, M.J.; Zwanzger, P.; Rupprecht, R.; Möller, H.J. Substance P serum levels are increased in major depression: preliminary results. Biol. Psychiatry., 2003, 53(6), 538-42.
24. Rimon, R.; Le Greves, P.; Nyberg, F.; Heikkila, L.; Salmela, L.; Terenius, L. Elevation of substance P-like peptides in the CSF of psychiatric patients. Biol. Phychiatry, 1984, 19(4), 509-516.
25. Vaeroy, H.; Helle, R.; Forre, O.; Kass, E.; Terenius, L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain, 1988, 32(1), 21-26.
26. Russell, I.J.; Orr, M.D.; Littman, B.; Vipraio, C.A.; Alboukrek, D.; Michalek, J.E.; Lopez, Y.; MacKillip, F. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum., 1994, 37(11), 1593-1601.
27. Russell, I.J. The promise of substance P inhibitors in fibromyalgia. Rheum. Dis. Clin. N. Am., 2002, 28(2), 329-342.
28. Pae, C.U.; Marks, D.M.; Patkar, A.A.; Masand, P.S.; Luyten, P.; Serretti, A. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. Expert Opin. Pharmacother., 2009, 10(10), 561-570.
29. Lieb, K.; Ahlvers, K.; Dancker, K.; Strohbusch, S.; Reincke, M.; Feige, B.; Berger, M.; Riemann, D.; Voderholzer, U. Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacol, 2002, 27(6), 1041-1049.
30. Gillberg, P.G.; Aquilonius, S.M.; Eckernäs, S.A.; Lundqvist, G.; Winblad, B. Choline acetyltransferase and substance P-like immuno-reactivity in the human spinal cord: changes in amyotrophic lateral sclerosis. Brain Res., 1982, 250(2), 394-397.
31. Matsuishi, T.; Nagamitsu, S.; Shoji, H.; Itoh, M.; Takashima, S.; Iwaki, T.; Shida, N.; Yamashita, Y.; Sakai, T.; Kato, H. Increased cerebrospinal fluid levels of substance P in patients with amyotrophic lateral sclerosis. Short communication. J. Neural. Transm., 1999, 106(9-10), 943-948.
32. Ito, H.; Kusaka, H.; Matsumoto, S.; Imai, T. Topographic involvement of the striatal efferents in basal ganglia of patients with adult-onset motor neuron disease with basophilic inclusions. Acta. Neuropathol., 1995, 89(6), 513-518.
33. Zachrisson, O.; Lindefors, N.; Brene, S. A tachykinin NK1 receptor antagonist, CP-122,721-1, attenuates kainic acid-induced seizure activity. Mol. Brain Res., 1998, 60(2), 291-295.
34. Liu, H.; Mazarati, A.M.; Katsumori, H.; Sankar, R.; Wasterlain, C.G. Substance P is expressed in hippocampal principal neurons during status epilepticus and plays a critical role in the maintenance of status epilepticus. Proc. Natl. Acad. Sci., 1999, 96(9), 5286-5291.
35. Liu, H.; Cao, Y.; Basbaum, A.I.; Mazarati, A.M.; Sankar, R.; Wasterlain, C.G. Resistance to excitotoxin-induced seizures and neuronal death in mice lacking the preprotachykinin A gene. Proc. Natl. Acad. Sci., 1999, 96(21), 12096-12101.
36. Bonner, T.I.; Affolter, H.U.; Young, A.C.; Young 3rd, W.S. A cDNA encoding the precursor of the rat neuropeptide, neurokinin B. Brain Res., 1987, 388, 243-249.
37. Krause, J.E.; Chirgwin, J.M.; Carter, M.S.; Xu, Z.S.; Hershey, A.D. Three rat preprotachykinin mRNAs encode the neuropeptides substance P and neurokinin A. Proc. Natl. Acad. Sci. U.S.A., 1987, 84, 881-885.
38. Gerfen, C.R.; Engber, T.M.; Mahan, L.C.; Susel, Z.; Chase, T.N.; Monsma, F.J. Jr; Sibley, D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science, 1990, 250(4986), 1429-1432.
39. Sonomura, T.; Nakamura, K.; Furuta, T.; Hioki, H.; Nishi, A.; Yamanaka, A.; Uemura, M.; Kaneko, T. Expression of D1 but not D2 dopamine receptors in striatal neurons producing neurokinin B in rats. Eur. J. Neurosci., 2007, 26, 3093-3103.
40. Furuta, T.; Mori, T.; Lee, T.; Kaneko, T. Third group of neostriatofugal neurons: neurokinin B-producing neurons that send axons predominantly to the substantia innominata. J. Comp. Neurol., 2000, 426, 279-296.
41. Sivam, S.P.; Krause, J.E. Tachykinin systems in the spinal cord and basal ganglia: influence of neonatal capsaicin treatment or dopaminergic intervention on levels of peptides. substance P-encoding mRNAs, and substance P receptor mRNA. J. Neurochem., 1992, 59, 2278-84.
42. Whitty, C.J.; Paul, M.A.; Bannon, M.J. Neurokinin receptor mRNA localization in human midbrain dopamine neurons. J. Comp. Neurol., 1997, 382(3), 394-400.
43. Shughrue, P.J.; Lane, M.V.; Merchenthaler, I. In situ hybridization analysis of the distribution of neurokinin-3 mRNA in the rat central nervous system. J. Comp. Neurol., 1996, 372, 395-314.
44. Chen, L.W.; Guan, Z.L.; Ding, Y.Q. Mesencephalic dopaminergic neurons expressing neuromedin K receptor (NK3): a double immunocytochemical study in the rat. Brain Res., 1998, 780, 150-154.
45. Preston, Z.; Richardson, P.J.; Pinnock, R.D.; Lee, K. NK-3 receptors are expressed on mouse striatal gamma-aminobutyric acid-ergic interneurones and evoke [(3)H] gamma-aminobutyric acid release. Neurosci. Lett. 2000, 284, 89-92.
46. Furuta, T.; Koyano, K.; Tomioka, R.; Yanagawa, Y.; Kaneko, T. GABAergic basal forebrain neurons that express receptor for neurokinin B and send axons to the cerebral cortex. J. Comp. Neurol., 2004, 473, 43-58.
47. Dawson, L.A.; Cato, K.J.; Scott, C.; Watson, J.M.; Wood, M.D.; Foxton, R.; de la Flor, R.; Jones, G.A.; Kew, J.N.; Cluderay, J.E.; Southam, E.; Murkitt, G.S.; Gartlon, J.; Pemberton, D.J.; Jones, D.N.; Davies, C.H.; Hagan, J. In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia. Neuropsychopharmacology, 2008, 33(7), 1642-1652.
48. Spooren, W.; Riemer, C.; Meltzer, H. NK3 receptor antagonists: the next generation of antipsychotics? Nat. Rev. Drug Discov., 2005, 4, 967-75.
49. Chen, L.W.; Yung, K.K.; Chan, Y.S.; Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson's disease. Curr. Drug Targets, 2004, 5(2), 197-206.
50. Garcia-Rill, E.; Houser, C.R.; Skiner, R.D.; Smith, W.; Woodward, D.J. Locomotion-inducing sites in the vicinity of the pedunculopontine nucleus. Brain Res. Bul., 1987, 18(6), 731-738.
51. Halliday, G.M.; Gai, W.P.; Blessing, W.W.; Geffen, L.B. Substance P-containing neurons in the pontomesencephalic tegmentum of the human brain. Neuroscience, 1990, 39(1), 81-96.
52. Gai, W.P.; Halliday, G.M.; Blumbergs, P.C.; Geffen, L.B.; Blessing, W.W. Substance P-containing neurons in the mesopontine tegmentum are severely affected in Parkinson's disease. Brain, 1991, 114(5), 2253-2267.
53. Mauborgne, A.; Javoy-Agid, F.; Legrand, J.C.; Agid, Y.; Cesselin, F. Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains. Brain Res., 1983, 268(1), 167-170.
54. Tenovuo, O.; Rinne, U.K.; Viljanen, M.K. Substance P immunoreactivity in the post-mortem parkinsonian brain. Brain Res., 1984, 303(1), 113-116.
55. Cui, Q.; Yung, W.; Chen, L. Effects of substance P on neuronal firing of pallidal neurons in parkinsonian rats. Neurosci. Res., 2008, 60(2), 162-169.
56. Burgunder, J.M.; Young 3rd, W.S. Distribution, projection and dopaminergic regulation of the neurokinin B mRNA-containing neurons of the rat caudate-putamen. Neuroscience, 1989, 32(2), 323-335.
57. Zhang, X.; Andren, P.E.; Chergui, K.; Svenningsson, P. Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease. Neuropharmacology, 2008, 54(7), 1143-1153.
58. Krasnova, I.N.; Bychkov, E.R.; Lioudyno, V.I.; Zubareva, O.E.; Dambinova, S.A. Intracerebroventricular administration of substance P increases dopamine content in the brain of 6-hydroxydopamine-lesioned rats. Neuroscience, 2000, 95(1), 113-117.
59. Salthun-Lassalle, B.; Traver, S.; Hirsch, E.C; Michel, P.P. Substance P, neurokinins A and B, and synthetic tachykinin peptides protect mesencephalic dopaminergic neurons in culture via an activity-dependent mechanism. Mol. Pharma., 2005, 68(5), 1214-1224.
60. Schols, L.; Vieira-Saecker, A.M.; Schols, S.; Przuntek, H.; Epplen, J.T.; Riess, O. Trinucleotide expansion within the MJD1 gene presents clinically as spinocerebellar ataxia and occurs most frequently in German SCA patients. Hum. Mol. Genet., 1995, 4, 1001-1005.
61. Schols, L.; Bauer, P.; Schmidt, T.; Schulte, T.; Riess, O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol., 2004; 3, 291-304.
62. Cooper, P.E.; Fernstrom, M.H.; Rostad, O.P.; Leeman, S.E.; Martin, J.B. The regional distribution of somatostatin, substance P and neurotensin in human brain. Brain Res., 1981, 218(1-2), 219-232.
63. Mai, J.K.; Stephens, P.H.; Hope, A.; Cuello, A.C. Substance P in the human brain. Neuroscience, 1986, 17(3), 709-739.
64. Cramer, H.; Rissler, K.; Rosler, N.; Strubel, D.; Schaudt D.; Kuntzmann, F. Immunoreactive substance P and somatostatin in the cerebrospinal fluid of senile parkinsonian patients. Eur. Neurol., 1989, 29(1), 1-5.
65. Matsuishi, T.; Sakai, T.; Nagamitsu, S.; Shoji, H.; Ueda, N.; Kaneko, S.; Kano, T.; Iwashita, H.; Kato, H. Decreased cerebrospinal fluid levels of substance P in Machado-Joseph disease. J. Neurol. Sci., 1996, 142(1-2), 107-110.
66. Vink, R.; Donkin, J.J.; Cruz, M.I.; Nimmo, A.J.; Cernak, I. A substance P antagonist increases brain intracellular free magnesium concentration after diffuse traumatic brain injury in rats. J. Am. Coll. Nutr., 2004, 23(5), 538S-540S.
67. McIntosh, T.K.; Smith, D.H.; Meaney, D.F.; Kotapka, M.J.; Gennarelli, T.A.; Graham, D.I. Neuropathological sequelae of traumatic brain injury: relationship to neurochemical and biomechanical mechanisms. Lab. Invest., 1996, 74, 315-342.
68. Lobato, R.D.; Sarabia, R.; Cordobes, F.; Rivas, J.J.; Adrados, A.; Cabrera, A.; Gomez, P.; Madera, A.; Lamas, E. Posttraumatic cerebral hemispheric swelling. Analysis of 55 cases studied with computerized tomography. J. Neurosurg., 1988, 68, 417-423.
69. Sarabia, R.; Lobato, R.D.; Rivas, J.J.; Cordobes, F.; Rubio, J.; Cabrera, A.; Gomez, P.; Munoz, M.J.; Madera, A. Cerebral hemisphere swelling in severe head injury patients. Acta. Neurochir. Suppl., 1988, 42, 40-46.
70. Woie, K.; Koller, M.E.; Heyeraas, K.J.; Reed, R.K. Neurogenic inflammation in rat trachea is accompanied by increased negativity of interstitial fluid pressure. Circ. Res., 1993, 73, 839-845.
71. Newbold, P.; Brain, S.D. An investigation into the mechanism of capsaicin-induced oedema in rabbit skin. Br. J. Pharmacol., 1995, 114, 570-577.
72. Nimmo, A.J.; Cernak, I.; Heath, D.L.; Hu, X.; Bennett, C.J.; Vink, R. Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats. Neuropeptides, 2004, 38, 40-47.
73. Malcangio, M.; Ramer, M.S.; Jones, M.G.; McMahon, S.B. Abnormal substance P release from the spinal cord following injury to primary sensory neurons. Eur. J. Neurosci., 2000, 12(1), 397-399.
74. Sharma, H.S.; Nyberg, F.; Olsson, Y.; Dey, P.K. Alteration of substance P after trauma to the spinal cord: an experimental study in the rat. Neuroscience, 1990, 38(1), 205-212.
75. Donkin, J.J.; Turner, R.J.; Hassan, I.; Vink, R. Substance P in traumatic brain injury. Prog. Brain Res., 2007, 161, 97-109.
76. Yu, Z.; Cheng, G.; Huang, X.; Li, K.; Cao, X. Neurokinin-1 receptor antagonist SR140333: a novel type of drug to treat cerebral ischemia. Neuroreport, 1997, 8(9-10), 2117-2119.
77. Cadieux, A.; Springall, D.R.; Mulderry, P.K.; Rodrigo, J.; Chatei, M.A.; Terenghi, G.; Bloom, S.R.; Polak, J.M. Occurrence, distribution and ontogeny of CGRP immunoreactivity in the rat lower respiratory tract: effect of capsaicin treatment and surgical denervations. Neuroscience, 1986, 19(2), 605-627.
78. Kashiba, H.; Ueda, Y.; Senba, E. Systemic capsaicin in the adult rat differentially affects gene expression for neuropeptides and neurotrophin receptors in primary sensory neurons. Neurosci., 1997, 76(1), 299-312.
79. Brookmeyer, R.; Gray, S.; Kawas, C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health, 1998, 88(9), 1337-1342.
80. Maudsley, S.; Martin, B.; Luttrell, L.M. G protein-coupled receptor signaling complexity in neuronal tissue: implications for novel therapeutics. Curr. Alzheimer Res., 2007, 4(1), 3-19.
81. Querfurth, H.W.; LaFerla, F.M. Alzheimer's disease. N. Engl. J. Med., 2010, 362(4), 329-344.
82. Maudsley, S.; Mattson, M.P. Protein twists and turns in Alzheimer disease. Nat. Med., 2006, 12(4), 392-393.
83. Martin, B.; Brenneman, R.; Becker, K.G.; Gucek, M.; Cole, R.N.; Maudsley, S. ITRAQ analysis of complex proteome alterations in 3xTgAD Alzheimer's mice: understanding the interface between physiology and disease. PLoS One, 2008, 3(7), e2750.
84. Kowall, N.W.; Quigley Jr., B.J.; Krause, J.E.; Lu, F.; Kosofsky, B.E.; Ferrante, R.J. Substance P and substance P receptor histochemistry in human neurodegenerative diseases. Regul. Pept., 1993, 46(1-2), 174-185.
85. Barker, R. Tachykinins, neurotrophism and neurodegenerative diseases: a critical review on the possible role of tachykinins in the aetiology of CNS diseases. Rev. Neurosci., 1996, 7(3), 187-214.
86. Crystal, H.A.; Davies, P. Cortical substance P-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type. J. Neurochem., 1982, 38(6), 1781-1784.
87. Beal, M.F.; Mazurek, M.F. Substance P-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex. Neurology, 1987, 37, 1205-1209.
88. Quigley Jr., B.J.; Kowall, N.W. Substance P-like immunoreactive neurons are depleted in Alzheimer's disease cerebral cortex. Neuroscience, 1991, 41(1), 41-60.
89. Yew, D.T.; Li, W.P.; Webb, S.E.; Lai, H.W.L.; Zhang, L. Neurotransmitters, peptides, and neural cell adhesion molecules in the cortices of normal elderly humans and Alzheimer patients: a comparison. Exp. Geron., 1999, 34(1), 117-133.
90. Armstrong, D.M.; Benzing, W.C.; Evans, J.; Terry, R.D.; Shields, D.; Hansen, L.A. Substance P and somatostatin coexist within neuritic plaques: implications for the pathogenesis of Alzheimer's disease. Neuroscience, 1989, 31, 663-671.
91. Pompei, P.; Severini, R.; Pediconi, D.; Angeletti, M.; Eleuteri, A.; Fattoretti, P.; Bertoni-Freddari, C.; Fioretti, E. Regulation of preprotachykinin-A gene expression in an animal model of Alzheimer's disease. J. Histochem. Cytochem., 2001, 49(11), 1469-1470.
92. Willis, M.; Hutter-Paier, B.; Wietzorrek, G.; Windisch, M.; Humpel, C.; Knaus, H.G.; Marksteiner, J. Localization and expression of substance P in transgenic mice overexpressing human APP751 with the London (V717I) and Swedish (K670M/N671L) mutations. Brain Res., 2007, 1143, 199-207.
93. Rösler, N.; Wichart, I.; Jellinger, K.A. Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients. J. Neural. Transm., 2001, 108(2), 231-246.
94. Marksteiner, J.; Saria, A.; Krause, J.E. Comparative distribution of neurokinin B-, substance P-and enkephalin-like immunore-activities and neurokinin B messenger RNA in the basal forebrain of the rat: evidence for neurochemical compartmentation. Neuroscience, 1992, 51, 107-120.
95. Marksteiner, J.; Sperk, G.; Krause, J.E. Distribution of neurons expressing neurokinin B in the rat brain: immunohistochemistry and in situ hybridization. J. Comp. Neurol., 1992, 317, 341-356.
96. Ahmed, M.M.; Hoshino, H.; Chikuma, T.; Yamada, M.; Kato, T. Effect of memantine on the levels of glial cells, neuropeptides, and peptide-degrading enzymes in rat brain regions of ibotenic acid-treated Alzheimer's disease model. Neuroscience, 2004, 126, 639-649.
97. Kart, E.; Jocham, G.; Muller, C.P.; Schlomer, C.; Brandao, M.L.; Huston, J.P.; Souza Silva, M.A. Neurokinin-1 receptor antagonism by SR140333: enhanced in vivo ACh in the hippocampus and promnestic post-trial effects. Peptides, 2004, 25, 1959-1969.
98. Souza Silva, M.A.; Hasenohrl, R.U.; Tomaz, C.; Schwarting, R.K.; Huston, J.P. Differential modulation of frontal cortex acetylcholine by injection of substance P into the nucleus basalis magnocellularis region in the freely-moving vs the anesthetized preparation. Synapse, 2000, 38, 243-253.
99. Li, S.H.; Li, X.J. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet., 2004, 20(3), 146-154.
100. Martin, B.; Golden, E.; Keselman, A.; Stone, M.; Mattson, M.P.; Egan, J.M.; Maudsley, S. Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body. Histol. Histopathol., 2008, 23(2), 237-250.
101. Landles, C.; Bates, G.P. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep., 2004, 5(10), 958-963.
102. Martin, B.; Golden, E.; Carlson, O.D.; Pistell, P.; Zhou, J.; Kim, W.; Frank, B.P.; Thomas, S.; Chadwick, W.A.; Greig, N.H.; Bates, G.P.; Sathasivam, K.; Bernier, M.; Maudsley, S.; Mattson, M.P.; Egan, J.M. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes, 2009, 58(2), 318-328.
103. Martin, J.B. Huntington's disease: new approaches to an old problem. The Robert Wartenberg lecture. Neurology, 1984, 34(8), 1059-1072.
104. Ferrante, R.J.; Kowall, N.W.; Richardson Jr., E.P.; Bird, E.D.; Martin, J.B. Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum. Neuroscience, 1986, 71(3), 283-288.
105. Augood, S.J.; Faull, R.L.M.; Love, D.R.; Emson, P.C. Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study. Neuroscience, 1996, 72(4), 1023-1036.
106. Richfield, E.K.; Vonsattel, J.P.; MacDonald, M.E.; Sun, Z.; Deng, Y.P.; Reiner, A. Selective loss of striatal preprotachykinin neurons in a phenocopy of Huntington's disease. Mov. Disord., 2002, 17(2), 327-332.
107. Graveland, G.A.; Williams, R.S.; DiFiglia, M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science, 1985, 227(4688), 770-773.
108. Park, S.; Yan, Y.; Satriotomo, I.; Vemuganti, R.; Dempsey, R.J. Substance P is a promoter of adult neural progenitor cell proliferation under normal and ischemic conditions. J. Neurosurg., 2007, 107(3), 593-599.
109. Morcuende, S.; Gadd, C.A.; Peters, M.; Moss, A.; Harris, E.A.; Sheasby, A.; Fisher, A.S.; De Filipe, C.; Mantyh, P.W.; Rupniak, N.M.J.; Giese, K.P.; Hunt, S.P. Increased neurogenesis and brain-derived neurotrophic factor in neurokinin-1 receptor gene knockout mice. Eur. J. Neurosci., 2003, 18(7), 1828-1836.
110. McCutcheon, J.E.; Fisher, A.S.; Guzdar, E.; Wood, S.A.; Lightman, S.L.; Hunt, S.P. Genetic background influences the behavioural and molecular consequences of neurokinin-1 receptor knockout. Euro. J. Neurosci., 2008, 27(3), 683-690.
111. Chadwick, W.; Magnus, T.; Martin, B.; Keselman, A.; Mattson, M.P.; Maudsley, S. Targeting TNF-alpha receptors for neurothera-peutics. Trends Neurosci., 2008, 31(10), 504-511.
112. Lieb, K.; Fiebich, B.L.; Berger, M.; Bauer, J.; Schulze-Osthoff, K. The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. J. Immunol., 1997, 159(10), 4952-4958.
113. Fiebich, B.L.; Schleicher, S.; Butcher, R.D.; Craig, A.; Lieb, K. The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independently from NF-kappa B. J. Immunol., 2000, 165(10), 5606-5611.
114. Marriott, I.; Bost, K.L. IL-4 and IFN-gamma up-regulate substance P receptor expression in murine peritoneal macrophages. J. Immunol., 2000, 165(1), 182-191.
115. Marriott, I.; Bost, K.L. Expression of authentic substance P receptors in murine and human dendritic cells. J. Neuroimmunol., 2001, 114(1-2), 131-141.
116. Martin, F.C.; Anton, P.A.; Gornbein, J.A.; Shanahan, F.; Merrill, J.E. Production of interleukin-1 by microglia in response to substance P: role for a non-classical NK-1 receptor. J. Neuroimmunol., 1993, 42(1), 53-60.
117. Kiefer, R.; Lindholm, D.; Kreutzberg, G.W. Interleukin-6 and transforming growth factor-beta 1 mRNAs are induced in rat facial nucleus following motoneuron axotomy. Eur. J. Neurosci., 1993, 5(7), 775-781.
118. Streit, W.J.; Hurley, S.D.; McGraw, T.S.; Semple-Rowland, S.L. Comparative evaluation of cytokine profiles and reactive gliosis supports a critical role for interleukin-6 in neuron-glia signaling during regeneration. J. Neurosci. Res., 2000, 61(1), 10-20.
119. Kalra, P.S.; Dube, M.G.; Kalra, S.P. The effects of interleukin 1 beta on the hypothalamic tachykinin, neurokinin A. Brain Res., 1994, 662(1-2), 178-184.
120. De Laurentiis, A.; Candolfi, M.; Pisera, D.; Seilicovich, A. Effects of lipopolysaccharide on neurokinin A content and release in the hypothalamic-pituitary axis. Regul. Pept., 2003, 111(1-3), 91-5.
121. McCluskey, L.P.; Lampson, L.A. Local immune regulation in the central nervous system by substance P vs glutamate. J. Neuroimmunol., 2001, 116(2), 136-146.
122. Amadoro, G.; Pieri, M.; Ciotti, M.T.; Carunchio, I.; Canu, N.; Calissano, P.; Zona, C.; Severini, C. Substance P provides neuroprotection in cerebellar granule cells through Akt and MAPK/Erk activation: evidence for the involvement of the delayed rectifier potassium current. Neuropharmacology, 2007, 52(6), 1366-1377.
123. Lallemend, F.; Lefebvre, P.P.; Hans, G.; Rigo, J.M.; Van de Water, T.R.; Moonen, G.; Malgrange, B. Substance P protects spiral ganglion neurons from apoptosis via PKC-Ca2+-MAPK/ERK pathways. J. Neurochem., 2003, 87(2), 508-521.
124. Calvo, N.; Reiriz, J.; Pérez-Navarro, E.; Alberch, J. Tachykinins protect cholinergic neurons from quinolinic acid excitotoxicity in striatal cultures. Brain Res., 1996, 740(1-2), 323-328.
125. Pieri, M.; Amadoro, G.; Carunchio, I.; Ciotti, M.T.; Quaresima, S.; Florenzano, F.; Calissano, P.; Possenti, R.; Zona, C.; Severini, C. SP protects cerebellar granule cells against beta-amyloid-induced apoptosis by down-regulation and reduced activity of Kv4 potassium channels. Neuropharmacology, 2010, 58(1), 268-276.
126. Yankner, B.A.; Duffy, L.K.; Kirschner, D.A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science, 1990, 250(4978), 279-282.
127. Kowall, N.W.; Beal, M.F.; Busciglio, J.; Duffy, L.K.; Yanker, B.A. An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc. Natl. Acad. Sci., 1991, 88(16), 7247-7251.
128. Sankhala, K.K.; Pandya, D.M.; Sarantopoulos, J.; Soefje, S.A.; Giles, F.J.; Chawla, S.P. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opin. Drug Metab. Toxicol., 2009, 5(12), 1607-1614.
129. Kramer, M.S.; Cutler, N.; Feighner, J.; Shrivastava, R.; Carman, J.; Sramek, J.J.; Reines, S.A.; Liu, G.; Snavely, D.; Wyatt-Knowles, E.; Hale, J.J.; Mills, S.G.; MacCoss, M.; Swain, C.J.; Harrison, T.; Hill, R.G.; Hefti, F.; Scolnick, E.M.; Cascieri, M.A.; Chicchi, G.G.; Sadowski, S.; Williams, A.R.; Hewson, L.; Smith, D.; Carlson, E.J.; Hargreaves, R.J.; Rupniak, N.M.J. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science, 1998, 281(5383), 1640-1645.
130. Rupniak, N.M.J.; Carlson, E.C.; Harrison, T.; Oates, B.; Seward, E.; Owen, S.; de Felipe, C.; Hunt, S.; Wheeldon, A. Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology, 2000, 39(8), 1413-1421.
131. Kramer, M.S.; Winokur, A.; Kelsey, J.; Preskorn, S.H.; Rothschild, A.J.; Snavely, D.; Ghosh, K.; Ball, W.A.; Reines, S.A.; Munjack, D.; Apter, J.T.; Cunningham. L.; Kling, M.; Bari, M.; Getson, A.; Lee, Y. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology, 2004, 29(2), 385-392.
132. Van Belle, S.; Lichinitser, M.R.; Navari, R.M.; Garin, A.M.; Decramer, M.L.A.; Riviere, A.; Thant, M.; Brestan, E.; Bui, B.; Eldridge, K.; De Smet, M.; Michiels, N.; Reinhardt, R.R.; Carides, A.D.; Evans, J.K.; Gertz, B.J. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer, 2002, 94(11), 3032-3041.
133. Kramer, J.H.; Mak, I.T.; Phillips, T.M.; Weglicki, W.B. Dietary magnesium intake influences circulating pro-inflammatory neuropeptide levels and loss of myocardial tolerance to postischemic stress. Exp. Biol. Med., 2003, 228(6), 665-673.
134. Heath, D.L.; Vink, R. Traumatic brain axonal injury produces sustained decline in intracellular free magnesium concentration. Brain Res., 1996, 738(1), 150-153.
135. Maudsley, S.; Martin, B.; Luttrell, L.M. The origins of diversity and specificity in G protein-coupled receptor signaling. J. Pharmacol. Exp. Ther., 2005, 314(2), 485-494.